Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2021 | Blinatumomab plus ponatinib for ALL update coming soon at EHA 2021

Nicholas Short • 25 May 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Antibodies Blinatumomab Ponatinib

Nicholas Short, MD, MD Anderson Cancer Center, Houston, TX, discussess an update on blinatumomab plus ponatinib which will be presented at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Nicholas Short, MD, has received consulting fees from Takeda Oncology and AstraZeneca; has received research funding from Takeda Oncology and Astellas Pharma Inc., and has received honoraria from Amgen.

More from Nicholas Short

Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL 2:17
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
Nicholas Short • 6 Dec 2025
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior? 2:20
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short • 6 Dec 2025
The current role of MRD in ALL subtypes 2:12
The current role of MRD in ALL subtypes
Nicholas Short • 3 Sep 2025
The prevalence and management of TP53-mutated ALL 2:22
The prevalence and management of TP53-mutated ALL
Nicholas Short • 3 Sep 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals